causal
Incentives push drug development toward late-stage
The current regulatory setup strongly incentivizes developing drugs for late-stage cancer rather than early-stage, because late-stage patients readily enroll in trials and reach endpoints faster, making trials cheaper and quicker; the prevalence of incremental drugs reflects this incentive structure, not the exhaustion of 'low-hanging fruit' or the absence of potential magic bullets.
causalpending
Speaker
Arthur DiamondEvidence Quote
“the current set-up strongly encourages development of new drugs for later stage. And, the reason is that it's a lot cheaper to do that”
Created: 6/13/2026, 12:15:58 AM
Your notes
Loading notes...